Cancer
Breast cancer in Changchun
长春 乳腺癌
4 hospitals in Changchun
Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for breast cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Changchun may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 77 papers led
- 51 papers ledNo open trial led
- 20 papers ledNo open trial led
- 2 papers ledNo open trial led
Breast cancer in every city Changchun on the disease page, with the national map
open trials on breast cancer with a hospital in Changchun
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Changchun as lead sponsor or study site. 2 of them are led by a hospital in Changchun. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingReal-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT06993506
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Hefei, Shanghai, Shijiazhuang, Wuhan, Xiamen, Yantai, Zhengzhou
- RecruitingA Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07281976
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Guangzhou, Harbin, Nanjing, Shenyang, Zhengzhou
- RecruitingA Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07347600
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou
- RecruitingA Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07876557
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Lanzhou, Nanchang, Nanjing, Qingdao, Shenyang, Shijiazhuang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou
- RecruitingA Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06738966
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Jinan
- RecruitingA Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06827236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBengbu, Changchun, Chengdu, Chongqing, Nanning, Shanghai, Xi'an
- RecruitingA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06841354
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanjing, Nanning, Taiyuan, Taizhou, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06966700
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Nanning, Shanghai, Urumqi, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingThe Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT06995118
Age 18 years to 70 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Guangzhou, Nanchang, Zhengzhou
- RecruitingA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07003074
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Hefei, Jinan, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Urumqi, Wuhan
- RecruitingClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07008976
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Fuzhou, Haikou, Hefei, Lanzhou, Linyi, Nanchang, Nanchong, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Zhengzhou
- RecruitingA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07043725
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou
- RecruitingJS207 Combination Therapy in Triple-negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07045311
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Dalian, Hangzhou, Harbin, Hefei, Nanjing, Qingdao, Shenyang, Shijiazhuang, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingTQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07047365
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 44 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guiyang, Haikou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Zhengzhou
- RecruitingA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07060807
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Taizhou, Urumqi, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07062965
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Wenzhou, Wuhan, Xi'an
- RecruitingBioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients
- Phase
- Phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT07096869
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
- RecruitingA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07174336
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Shanghai, Shantou, Tianjin, Wuhan
- RecruitingA Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps
- Phase
- Not given
- Started
- 2025-11
- Posted
- Registry
- NCT07244094
Age 18 years to 95 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteChangchun, Hangzhou
- RecruitingA Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT07673029
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou
- RecruitingBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase
- Phase 1/Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06324357
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingObservational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06918262
Age not stated (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- RecruitingA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05646862
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Tianjin, Wuhan
- RecruitingEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT05696626
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingPhase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2023-04
- Posted
- Registry
- NCT05744687
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesAnyang, Beijing, Changchun, Fuzhou, Guangzhou, Luoyang, Yinchuan
- RecruitingSafety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2023-09
- Posted
- Registry
- NCT05860465
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanjing, Shenyang, Shijiazhuang, Tianjin, Xi'an, Yinchuan
- RecruitingEfficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
- Phase
- Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT05872347
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Guangzhou, Hangzhou, Harbin, Hefei, Luoyang, Nanjing, Nanning, Shijiazhuang, Tianjin, Urumqi, Wuhan, Xiangyang, Yinchuan, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2023-09
- Posted
- Registry
- NCT05894239
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Hangzhou, Jinan, Luoyang, Nanchang, Nanning, Shijiazhuang, Tianjin, Wuhan
- RecruitingA Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
- Phase
- Phase 1/Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT06064812
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- RecruitingJSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06079983
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingA Study of YL202 in Selected Patients With Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06107686
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou
- RecruitingJAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05490472
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changchun, Jinan
- RecruitingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05579366
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan
- RecruitingA Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2022-01
- Posted
- Registry
- NCT05851014
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou
- RecruitingAlbumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
- Phase
- Phase 4
- Started
- 2021-07
- Posted
- Registry
- NCT04136782
Age 18 years to 70 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical University; 3 listed hospitals as study sitesChangchun, Harbin, Shenyang
- RecruitingSj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
- Phase
- Not given
- Started
- 2021-07
- Posted
- Registry
- NCT04476485
Age 18 years to 70 years; women only (registered criteria)
Led by Shengjing Hospital of China Medical University; 3 listed hospitals as study sitesChangchun, Harbin, Shenyang
- RecruitingEffect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
- Phase
- Phase 4
- Started
- 2021-06
- Posted
- Registry
- NCT04790305
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou
- RecruitingA Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast
- Phase
- Phase 1
- Started
- 2013-01
- Posted
- Registry
- NCT02897700
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai
- Enrolling by invitationEfficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment
- Phase
- Not given
- Started
- 2025-05
- Posted
- Registry
- NCT06914661
Age 18 years to 100 years (registered criteria)
Led by First Hospital of Jilin UniversityChangchun
- Enrolling by invitationA Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07376629
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Changchun
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Hospital of Changchun University of Chinese Medicine长春中医药大学附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | 6 | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | 1 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | |
| China-Japan Union Hospital, Jilin University吉林大学白求恩第三医院(中日联谊医院) | 0 | none | 21 | 22 | 31 | 14 | 51 | 22 | none | 0 | 0 | 13 | 1 | 1 | 0 | 4 | none | none | none | 10 | none | none | none | none | none | 3 | none | 2 | 2 | none | none | 15 | 4 | 2 | none | 0 | none | 1 | none | 1 | 0 | none | none | none | 0 | none | 0 | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | |
| First Hospital of Jilin University吉林大学第一医院 | 3 | 5 | 761 open | 417 open | 1121 open | 27 | 772 open | 561 open | 1 | 3 | 0 | 17 | 0 | 7 | 2 | 174 open | 0 | 2 | 4 | 243 open | none | 0 | 2 | 1 | none | 11 | none | 1 | 4 | 2 | none | 202 open | 9 | 2 | 5 | 2 | none | 1 | none | 2 | 0 | 1 | none | 0 | 3 | 0 | 71 open | 1 | none | 0 | 11 | 1 | none | none | none | none | 0 | none | none | none | none | |
| Jilin Cancer Hospital吉林省肿瘤医院 | none | 0 | 4 | 0 | 39 | none | 2 | 1 | none | none | none | none | 0 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jilin Heart Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jilin Province FAW General Hospital吉林省一汽总医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jilin Province People's Hospital吉林省人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Hospital of Jilin University吉林大学第二医院 | 0 | 1 | 15 | 17 | 37 | 8 | 20 | 10 | none | 1 | none | 11 | 1 | 1 | 0 | 4 | none | none | none | 6 | none | none | none | none | none | none | 5 | none | none | none | none | 123 open | 2 | 1 | none | 0 | none | 7 | none | 2 | none | none | 1 | none | 1 | 0 | 7 | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Changchun.
- Nasopharyngeal carcinoma 0
- Hepatocellular carcinoma 21
- Stomach cancer 22
- Lung cancer 31
- Pancreatic cancer 14
- Breast cancer 51
- Glioma 22
- Retinoblastoma 0
- Chordoma 0
- Osteosarcoma 13
- Gastrointestinal stromal tumour 1
- Neuroblastoma 1
- Ewing sarcoma 0
- Multiple myeloma 4
- Lymphoma 10
- Neuromyelitis optica spectrum disorder 3
- Myasthenia gravis 2
- Moyamoya disease 2
- Coronary heart disease 15
- Congenital heart disease 4
- Scoliosis 2
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 1
- Spinal muscular atrophy 0
- Behçet disease 0
- IgA nephropathy 0
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 1
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 5
- Hepatocellular carcinoma 761 open
- Stomach cancer 417 open
- Lung cancer 1121 open
- Pancreatic cancer 27
- Breast cancer 772 open
- Glioma 561 open
- Hepatoblastoma 1
- Retinoblastoma 3
- Chordoma 0
- Osteosarcoma 17
- Gastrointestinal stromal tumour 0
- Neuroblastoma 7
- Ewing sarcoma 2
- Multiple myeloma 174 open
- B-cell acute lymphoblastic leukaemia 0
- Aplastic anaemia 2
- Haemophagocytic lymphohistiocytosis 4
- Lymphoma 243 open
- Haemophilia A 0
- Atypical haemolytic uraemic syndrome 2
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 11
- Myasthenia gravis 1
- Moyamoya disease 4
- Wilson disease 2
- Coronary heart disease 202 open
- Congenital heart disease 9
- Scoliosis 2
- Anti-NMDA receptor encephalitis 5
- Takayasu arteritis 2
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 2
- Spinal muscular atrophy 0
- Fabry disease 1
- Duchenne muscular dystrophy 0
- Behçet disease 3
- Alport syndrome 0
- IgA nephropathy 71 open
- Gaucher disease 1
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 11
- Primary sclerosing cholangitis 1
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 0
- Oesophageal squamous cell carcinoma 1
- Hepatocellular carcinoma 15
- Stomach cancer 17
- Lung cancer 37
- Pancreatic cancer 8
- Breast cancer 20
- Glioma 10
- Retinoblastoma 1
- Osteosarcoma 11
- Gastrointestinal stromal tumour 1
- Neuroblastoma 1
- Ewing sarcoma 0
- Multiple myeloma 4
- Lymphoma 6
- IgG4-related disease 5
- Coronary heart disease 123 open
- Congenital heart disease 2
- Scoliosis 1
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 7
- Amyotrophic lateral sclerosis 2
- Pompe disease 1
- Behçet disease 1
- Alport syndrome 0
- IgA nephropathy 7
- Primary biliary cholangitis 2
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for breast cancer.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Changchun on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.